{"DataElement":{"publicId":"5094920","version":"1","preferredName":"Primary Immunodeficiency Post Allogeneic Bone Marrow Transplantation Disease or Survival End Point Type","preferredDefinition":"Disease or survival endpoint applied to a patient with primary immunodeficiency condition treated with allogeneic bone marrow transplantation (BMT).","longName":"IMMN_POSTALL_END_TP","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5094895","version":"1","preferredName":"Primary Immunodeficiency Post Allogeneic Bone Marrow Transplantation Disease or Survival End Point","preferredDefinition":"_The result of an action._Primary immunodeficiencies (PIs) are a heterogeneous group of disorders, which affect cellular and humoral immunity or non-specific host defense mechanisms mediated by complement proteins, and cells such as phagocytes and natural killer (NK) cells. These disorders of the immune system cause increased susceptibility to infection, autoimmune disease, and malignancy. Most of PIs are due to genetic defects that affect cell maturation or function at different levels during hematopoiesis. Disruption of the cellular immunity is observed in patients with defects in T cells or both T and B cells. These cellular immunodeficiencies comprise 20% of all PIs. Disorders of humoral immunity affect B-cell differentiation and antibody production. They account for 70% of all PIs._Happening at a time subsequent to a reference time; later in time or order._A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Continuance of life or existence especially under adverse conditions; includes methods and philosophy of survival._A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.","longName":"5094892v1.0:5094893v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"5094892","version":"1","preferredName":"Primary Immunodeficiency Pathway Post Allogeneic Bone Marrow Transplantation","preferredDefinition":"Primary immunodeficiencies (PIs) are a heterogeneous group of disorders, which affect cellular and humoral immunity or non-specific host defense mechanisms mediated by complement proteins, and cells such as phagocytes and natural killer (NK) cells. These disorders of the immune system cause increased susceptibility to infection, autoimmune disease, and malignancy. Most of PIs are due to genetic defects that affect cell maturation or function at different levels during hematopoiesis. Disruption of the cellular immunity is observed in patients with defects in T cells or both T and B cells. These cellular immunodeficiencies comprise 20% of all PIs. Disorders of humoral immunity affect B-cell differentiation and antibody production. They account for 70% of all PIs.:Happening at a time subsequent to a reference time; later in time or order.:A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor.","longName":"C91500:C38008:C15369","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Immunodeficiency Pathway","conceptCode":"C91500","definition":"Primary immunodeficiencies (PIs) are a heterogeneous group of disorders, which affect cellular and humoral immunity or non-specific host defense mechanisms mediated by complement proteins, and cells such as phagocytes and natural killer (NK) cells. These disorders of the immune system cause increased susceptibility to infection, autoimmune disease, and malignancy. Most of PIs are due to genetic defects that affect cell maturation or function at different levels during hematopoiesis. Disruption of the cellular immunity is observed in patients with defects in T cells or both T and B cells. These cellular immunodeficiencies comprise 20% of all PIs. Disorders of humoral immunity affect B-cell differentiation and antibody production. They account for 70% of all PIs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Allogeneic Bone Marrow Transplantation","conceptCode":"C15369","definition":"A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1CA2-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"ONEDATA","dateModified":"2015-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5094893","version":"1","preferredName":"Disease or Disorder Survival End Point","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Continuance of life or existence especially under adverse conditions; includes methods and philosophy of survival.:A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.","longName":"C2991:C17177:C25212","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Survival","conceptCode":"C17177","definition":"Continuance of life or existence especially under adverse conditions; includes methods and philosophy of survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"End Point","conceptCode":"C25212","definition":"A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1CB4-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"ONEDATA","dateModified":"2015-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1CC5-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"To support Primary Immunodeficiency post Allo-BMT trial in NCI CCR. 12/27/2015.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5094912","version":"1","preferredName":"Allogeneic Bone Marrow Transplantation End Point Type","preferredDefinition":"A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor._A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment._Something distinguishable as an identifiable class based on common qualities.","longName":"ALLO_BMT_END_TP","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Relapse of Prior Malignancy","valueDescription":"Prior Malignancy Relapse post-allogeneic BMT","ValueMeaning":{"publicId":"5094913","version":"1","preferredName":"Prior Malignancy Relapse post-allogeneic BMT","longName":"5094913","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.: A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor.: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Allogeneic Bone Marrow Transplantation","conceptCode":"C15369","definition":"A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1D02-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"27F7C129-1D1B-C415-E050-BB89AD43549B","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"ONEDATA","dateModified":"2015-12-28","deletedIndicator":"No"},{"value":"Transplant Related Mortality (TRM)","valueDescription":"Transplant Related Mortality","ValueMeaning":{"publicId":"5094914","version":"1","preferredName":"Transplant Related Mortality","longName":"5094914","preferredDefinition":"A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor.: The ratio of deaths in an area to the population of that area, expressed as deaths per 1000 per year.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allogeneic Bone Marrow Transplantation","conceptCode":"C15369","definition":"A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mortality Rate","conceptCode":"C16880","definition":"The proportion of deaths occurring in a population over a specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1D25-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"27F7C129-1D3E-C415-E050-BB89AD43549B","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"ONEDATA","dateModified":"2015-12-28","deletedIndicator":"No"},{"value":"Overall Survival","valueDescription":"Overall Survival post-allogeneic BMT","ValueMeaning":{"publicId":"5094915","version":"1","preferredName":"Overall Survival post-allogeneic BMT","longName":"5094915","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.: A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor.: Continuance of life or existence especially under adverse conditions; includes methods and philosophy of survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Allogeneic Bone Marrow Transplantation","conceptCode":"C15369","definition":"A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Survival","conceptCode":"C17177","definition":"Continuance of life or existence especially under adverse conditions; includes methods and philosophy of survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1D48-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"27F7C129-1D61-C415-E050-BB89AD43549B","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"ONEDATA","dateModified":"2015-12-28","deletedIndicator":"No"},{"value":"Event-free Survival","valueDescription":"Event-free Survival post-allogeneic BMT","ValueMeaning":{"publicId":"5094916","version":"1","preferredName":"Event-free Survival post-allogeneic BMT","longName":"5094916","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.: A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor.: The length of time after treatment during which a patient survives with no sign of a particular complication of disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Allogeneic Bone Marrow Transplantation","conceptCode":"C15369","definition":"A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Event-Free Survival","conceptCode":"C96340","definition":"The length of time after treatment during which a patient survives with no sign of a particular complication of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1D6B-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"27F7C129-1D84-C415-E050-BB89AD43549B","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"ONEDATA","dateModified":"2015-12-28","deletedIndicator":"No"},{"value":"Disease-free Survival","valueDescription":"Disease-free Survival post-allogeneic BMT","ValueMeaning":{"publicId":"5094917","version":"1","preferredName":"Disease-free Survival post-allogeneic BMT","longName":"5094917","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.: A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor.: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Allogeneic Bone Marrow Transplantation","conceptCode":"C15369","definition":"A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease-Free Survival","conceptCode":"C17751","definition":"The length of time after treatment for a specific disease during which a patient survives with no sign of recurrence of the disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1D8E-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"27F7C129-1DA7-C415-E050-BB89AD43549B","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"ONEDATA","dateModified":"2015-12-28","deletedIndicator":"No"},{"value":"Reversal of Immune Dysfunction","valueDescription":"Immune Dysfunction Reversal","ValueMeaning":{"publicId":"5094918","version":"1","preferredName":"Immune Dysfunction Reversal","longName":"5094918","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.: A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor.: A disorder resulting from an abnormality in the immune system.: A change in something from one state to the opposite state.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Allogeneic Bone Marrow Transplantation","conceptCode":"C15369","definition":"A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Immune System Disorder","conceptCode":"C3507","definition":"A disorder resulting from an abnormality in the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reversal","conceptCode":"C125005","definition":"A change in something from one state to the opposite state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1DB1-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"27F7C129-1DCA-C415-E050-BB89AD43549B","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"ONEDATA","dateModified":"2015-12-28","deletedIndicator":"No"},{"value":"Reversal of Disease Phenotype","valueDescription":"Disease Phenotype Reversal","ValueMeaning":{"publicId":"5094919","version":"1","preferredName":"Disease Phenotype Reversal","longName":"5094919","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.: A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.: The outward appearance of the individual. It is the product of interactions between genes and between the genotype and the environment. This includes the killer phenotype, characteristic of YEASTS.: A change in something from one state to the opposite state.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Allogeneic Bone Marrow Transplantation","conceptCode":"C15369","definition":"A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Phenotype","conceptCode":"C16977","definition":"The assemblage of traits or outward appearance of an individual. It is the product of interactions between genes and between genes and the environment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reversal","conceptCode":"C125005","definition":"A change in something from one state to the opposite state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1DD4-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"27F7C129-1DED-C415-E050-BB89AD43549B","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"ONEDATA","dateModified":"2015-12-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5094911","version":"1","preferredName":"Allogeneic Bone Marrow Transplantation End Point Type","preferredDefinition":"A procedure in which a person receives stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor.:A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.:Something distinguishable as an identifiable class based on common qualities.","longName":"C15369:C25212:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allogeneic Bone Marrow Transplantation","conceptCode":"C15369","definition":"A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"End Point","conceptCode":"C25212","definition":"A place of termination or completion. This may be a primary or secondary outcome variable used to judge the effectiveness of a treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1CDC-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"ONEDATA","dateModified":"2015-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F7C129-1CED-C415-E050-BB89AD43549B","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"REEVESD","dateModified":"2016-05-12","changeDescription":"Supports primary immunodeficiency post allogeneic BMT trial from NCI CCR. 12/28/2015.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Disease or Survival End Point","type":"Preferred Question Text","description":"Disease or Survival End Point","url":null,"context":"CCR"}],"origin":"C3D:Central Cancer Clinical Database","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"27F820F3-DAA1-1A5B-E050-BB89AD43527C","latestVersionIndicator":"Yes","beginDate":"2015-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-12-28","modifiedBy":"REEVESD","dateModified":"2015-12-28","changeDescription":"Curated to support NCI CCR primary immunodeficiency clinical trial. 12/28/2015.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}